Tumor And Renal Response In Patients With Newly Diagnosed Multiple Mieloma And Renal Failure Treated With Bortezomib And Dexamethasone: Results Of A Prospective Phase Ii Trial From Pethema/Gem

Background: Renal failure (RF) is present in about 20% of patients with newly diagnosed multiple myeloma (MM) and is associated with a poor outcome. Bortezomib-based therapy has shown significant activity in patients with RF, including a higher rate of renal recovery when compared with previous regimens. We report the results of a prospective phase II trial for patients with newly diagnosed MM and RF treated with bortezomib and dexamethasone (VD) (RENVEL: www.clinicaltrials.gov NCT 01084837).